The Platform Technology Approach to mRNA Product Development and Regulation

Area of Science:

• Biotechnology
• Regulatory Science
• Pharmaceutical Development

Background:

• Messenger RNA (mRNA) medicinal products, particularly lipid nanoparticle (LNP) formulations, represent a versatile platform technology.
• The established development, manufacturing, and analytical processes for mRNA-LNP products facilitate adaptation across various diseases.
• Maintaining momentum from the COVID-19 pandemic's mRNA vaccine rollout is crucial for future therapeutic advancements.

Purpose of the Study:

• To propose modifications to existing regulatory requirements for mRNA products from a platform perspective.
• To address the development and regulatory needs for products with varying mRNA sequences and LNP compositions.
• To outline considerations for novel mRNA modalities, including self-amplifying mRNA, personalized oncology mRNA, and general mRNA therapeutics.

Main Methods:

• Review of current regulatory frameworks for mRNA products.
• Analysis of platform technology principles applied to mRNA development.
• Identification of necessary data for regulatory submissions across diverse mRNA product types.

Main Results:

• A proposed set of regulatory modifications based on a platform approach for quality, manufacturing, preclinical, and clinical data.
• Considerations for regulatory pathways accommodating variations in mRNA sequences and LNP composition.
• Framework for evaluating self-amplifying mRNA, personalized oncology mRNA, and mRNA therapeutics.

Conclusions:

• Adopting a platform approach for mRNA therapeutics offers significant benefits, including reduced costs and faster patient access.
• A predictable regulatory pathway is essential for academic and commercial development of mRNA products.
• The mRNA platform approach can serve as a model for other therapeutic and vaccine development, enhancing efficiency and regulatory review.